Poster Presentations dietary supplementation in patients with IBD, and particularly Crohn' s disease. Subject numbers are relatively small and statistical significance was not achieved, but no other study on the subject is placebo controlled and double blinded, or has dietary oral calcium intake data for subjects. Although tolerability of the medication was good, results do not provide enough evidence to support the use of oral calcium and vitamin D supplements in all patients with inflammatory bowel disease. All patients were affected by severe UC; 3 (1 F and 2 M) with left colitis and 1 F with pancolitis. A clinical picture compatible with hyperthyroidism (blood suppression of TSH, marked blood increase of FT3, FT4 and anti TSH receptor > 15 mU/L n.v.0-1) was present in a female 60 year old and a surgical resection for was needed for histological diagnosis of severe dysplasia; only medical therapy (metimazole to step down from a starting dose of 30 mg/day) for 2 years was needed and, actually, the patient is well. 2 M and 1 F had a diagnosis of autoimmune hypothyroidism (Increased blood level of TSH (mean 10 MU/L range 5-15 n.v. 0.6-5), low blood level of FT4 (mean 7 ng/ml range 3-8.5 n.v. 9-18) and presence of anti tireoglobulin and anti microsomial antibodies) and they actually are treated with L-Tiroxine therapy (mean dosage 75 mcg/day range 50-200). In all patients ultrasound didn' t reveal thyroid nodules, but a marked ultrasound pattern alteration. Conclusion: Thyroid function should be considered in patients affected by UC and, particularly, in patients with left colitis and pancolitis associated to severe disease activity. 
P103 QUANTITATIVE EXPRESSION OF CD64 ON POLYMORPHONUCLEAR NEUTROPHILS: A NEW DIAGNOSTIC TOOL IN IBD
Background: Intestinal bacterial infections and non-inflammatory intestinal disorders, such as lactose or fructose intolerance (LFI), may present with symptoms similar to active inflammatory bowel disease (IBD). However, there is currently no discriminative laboratory marker available. Here, we investigated the utility of CD64 as a tool in differential diagnosis of IBD. Patients and Methods: Expression of CD64 by PMN was determined by FACS analysis using a fluorescence quantitation kit (QuantibriteTM PE, BD Biosciences). We investigated patients with active (n=27) or inactive (n=49) IBD, infectious enterocolitis (n=24, i.e. Campylobacter [n = 13], Salmonella [n =7], Shigella [n = 1], and Clostridium difficile [n = 3]).), LFI (n=32), and healthy subjects (n=28). (Clinical measures of disease activity included the Crohn' s disease activity index (CDAI) for patients with Crohn' s disease (n=52), and the colitis activity index (CAI) for patients with ulcerative colitis (n=24). Active IBD was defined as CDAI > 150 and CAI > 6, respectively. Statistical comparisons of means were done by t-test. Correlations were assessed by means of Spearman' s correlation coefficient. Receiver operating characteristic curves were generated in order to define discriminative cut off values of CD64 expression. Data are given as median and range from the 25th to the 75th quartile (IQR). Results: The quantitative expression of CD64 was significantly higher in patients with IBD (1125 IBD ( , 621-2083 , than in healthy subjects (569, 387-756, p<0 .01), or in patients with LFI (531, p<0.001) . In patients with active IBD the CD64 expression was significantly higher (2158, 1230-7709) than in patients in remission (755, 438-2109, p<0.0001) . CD64 correlated with the CDAI (110, 44-197; 0.55, p<0 .0001), the CAI (2, 0-5; 0.63, p<0.0001), and with serum of levels of CRP (0.93, 0.4-2.67; 0.65, p<0.0001). With a cut off point of 800 CD64 had a 96% sensitivity and a 97% specificity in discriminating between LFI and active IBD. In patients with infectious enterocolitis (15209, ) the quantitative expression of CD64 was significantly higher than in patients with active IBD (4058±3590, p<0.001). With a cut off point of 10000 CD64 had a 88% sensitivity and a 93% specificity in discriminating between infectious enterocolitis and active IBD. Conclusion: Assessment of the quantitative expression of CD64 on PMN allows to discriminating between active and remitting IBD, infectious enterocolitis, and LFI. Thus, CD64 may serve as a valuable diagnostic tool for the differential diagnosis and monitoring of IBD.
